Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects

International Immunopharmacology

Volumn 11, Issue 11, 2011, Pages 1796-1801

  Sweeney, Matthew E ^a,b   Slusser, Joyce G ^c   Lynch, Sharon G ^a   Benedict, Stephen H ^d   Garcia, Sharon L ^a   Rues, Laura ^a,b   Levine, Steven M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b ROCKHURST UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

CD4 T cells; CD8 T cells; Deferiprone; Multiple sclerosis; Regulatory T cells; T cell proliferation

Indexed keywords

CD28 ANTIBODY; CD3 ANTIBODY; DEFERIPRONE; INTERLEUKIN 2; LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIGENS, CD28; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PYRIDONES; YOUNG ADULT;

EID: 80054992674     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.07.007     Document Type: Article

References (26)

1. F. Sellebjerg, D. Barnes, G. Filippini, R. Midgard, X. Montalban, and P. Rieckmann EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses Eur J Neurol 12 2005 939 946 (Pubitemid 41820048)
2. K.M. Myhr, and S.I. Mellgren Corticosteroids in the treatment of multiple sclerosis Acta Neurol Scand Suppl 189 2009 73 80
3. P.R. Lyons, P.K. Newman, and M. Saunders Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects J Neurol Neurosurg Psychiatry 51 1988 285 287 (Pubitemid 18055141)
4. E.M. Frohman, A. Shah, E. Eggenberger, L. Metz, R. Zivadinov, and O. Stüve Corticosteroids for multiple sclerosis: I. Application for treating exacerbations Neurotherapeutics 4 2007 618 626 (Pubitemid 47499290)
5. B.W. Thrower Relapse management in multiple sclerosis Neurologist 15 2009 1 5 [Review]
6. H. Tumani Corticosteroids and plasma exchange in multiple sclerosis J Neurol 255 Suppl. 6 2008 36 42
7. L. Steinman, and S.S. Zamvil How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis Ann Neurol 60 2006 12 21
8. M.R. Emerson, R.J. Gallagher, J.G. Marquis, and S.M. LeVine Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design Comp Med 59 2009 112 128
9. K.M. Mitchell, A.L. Dotson, K.M. Cool, A. Chakrabarty, S.H. Benedict, and S.M. LeVine Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis Mult Scler 13 2007 1118 1126 (Pubitemid 351541415)
10. T. Vollmer The natural history of relapses in multiple sclerosis J Neurol Sci 256 Suppl. 1 2007 S5 S13 (Pubitemid 46560640)
11. H.L. Weiner The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65 2009 239 248
12. G.C. Del Vecchio, F. Schettini, L. Piacente, A. De Santis, P. Giordano, and D. De Mattia Effects of deferiprone on immune status and cytokine pattern in thalassaemia major Acta Haematol 108 2002 144 149 (Pubitemid 35316749)
13. W.J. Bartfay, D.C. Lehotay, G.D. Sher, E. Bartfay, B. Tyler, and X. Luo Erythropoiesis: comparison of cytotoxic aldehyde generation in beta-thalassemia patients chelated with deferoxamine or deferiprone (L1) versus NO chelation Hematology 4 1999 67 76 (Pubitemid 29484062)
14. C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, and L. Kappos Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 2005 840 846 (Pubitemid 41746873)
15. F.D. Lublin, and S.C. Reingold Defining the clinical course of multiple sclerosis: results of an international survey Neurology 46 1996 907 911 (Pubitemid 26134623)
16. A.L. Putnam, T.M. Brusko, M.R. Lee, W. Liu, G.L. Szot, and T. Ghosh Expansion of human regulatory T-cells from patients with type 1 diabetes Diabetes 58 2009 652 662
17. European Medicines Agency Ferriprox, INN-deferiprone. Annex I. Summary of product characteristics, WC500022050 www.ema.europa.eu
18. A.M. Fredenburg, R.K. Sethi, D.D. Allen, and R.A. Yokel The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat Toxicology 108 1996 191 199
19. N. Boddaert, K.H. Le Quan Sang, A. Rötig, A. Leroy-Willig, and S. Gallet Selective iron chelation in Friedreich ataxia: biologic and clinical implications Blood 110 2007 401 408 (Pubitemid 47026862)
20. M. Clerici, M. Saresella, D. Trabattoni, L. Speciale, S. Fossati, and S. Ruzzante Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease J Neuroimmunol 121 2001 88 101 (Pubitemid 34008456)
21. US Department of Health and Human Services Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers Pharmacol Toxicol 2005
22. C.E. Cooper, G.R. Lynagh, K.P. Hoyes, R.C. Hider, R. Cammack, and J.B. Porter The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase J Biol Chem 271 1996 20291 20299 (Pubitemid 26281794)
23. C. Warnke, G. Meyer Zu Hörste, H.P. Hartung, O. Stüve, and B.C. Kieseier Review of teriflunomide and its potential in the treatment of multiple sclerosis Neuropsychiatr Dis Treat 5 2009 333 340
24. S.J. Khoury, C.R.G. Guttmann, E.J. Orav, R. Kikinis, F.A. Jolesz, and H.L. Weiner Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis Arch Neurol 57 2000 1183 1189 (Pubitemid 30644666)
25. K. Venken, N. Hellings, K. Hensen, J.L. Rummens, R. Medaer, and M.B. D'hooghe Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression J Neurosci Res 83 2006 1432 1446 (Pubitemid 43844989)
26. A. Namdar, B. Nikbin, M. Ghabaee, A. Bayati, and M. Izad Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study J Neuroimmunol 218 2010 120 124